The potential role of brain renin-angiotensin system in the neuropathology of Parkinson disease: Friend, foe or turncoat?

Autor: Al-Qahtani Z; Neurology Section, Internal Medicine Department, College of Medicine, King khaled university, Abha, Saudi Arabia., Al-Kuraishy HM; Clinical pharmacology and medicine, college of medicine, Mustansiriyah University, Baghdad, Iraq., Al-Gareeb AI; Clinical pharmacology and medicine, college of medicine, Mustansiriyah University, Baghdad, Iraq., Albuhadily AK; Clinical pharmacology and medicine, college of medicine, Mustansiriyah University, Baghdad, Iraq., Ali NH; Department of Internal Medicine, Medical College, Najran University, Najran, Saudi Arabia., Alexiou A; University Centre for Research & Development, Chandigarh University, Mohali, India.; Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.; Department of Research & Development, Funogen, Athens, Greece.; Department of Research & Development, AFNP Med, Wien, Austria., Papadakis M; Department of Surgery II, University Hospital Witten-Herdecke, Wuppertal, Germany., Saad HM; Department of Pathology, Faculty of Veterinary Medicine, Matrouh University, Matrouh, Egypt., Batiha GE; Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, AlBeheira, Egypt.
Jazyk: angličtina
Zdroj: Journal of cellular and molecular medicine [J Cell Mol Med] 2024 Jun; Vol. 28 (12), pp. e18495.
DOI: 10.1111/jcmm.18495
Abstrakt: Parkinson disease (PD) is one of the most common neurodegenerative diseases of the brain. Of note, brain renin-angiotensin system (RAS) is intricate in the PD neuropathology through modulation of oxidative stress, mitochondrial dysfunction and neuroinflammation. Therefore, modulation of brain RAS by angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) may be effective in reducing the risk and PD neuropathology. It has been shown that all components including the peptides and enzymes of the RAS are present in the different brain areas. Brain RAS plays a critical role in the regulation of memory and cognitive function, and in the controlling of central blood pressure. However, exaggerated brain RAS is implicated in the pathogenesis of different neurodegenerative diseases including PD. Two well-known pathways of brain RAS are recognized including; the classical pathway which is mainly mediated by AngII/AT1R has detrimental effects. Conversely, the non-classical pathway which is mostly mediated by ACE2/Ang1-7/MASR and AngII/AT2R has beneficial effects against PD neuropathology. Exaggerated brain RAS affects the viability of dopaminergic neurons. However, the fundamental mechanism of brain RAS in PD neuropathology was not fully elucidated. Consequently, the purpose of this review is to disclose the mechanistic role of RAS in in the pathogenesis of PD. In addition, we try to revise how the ACEIs and ARBs can be developed for therapeutics in PD.
(© 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: